All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

EU approves Merck & Co.'s Ezmekly, first MEK inhibitor therapy for neurofibromatosis type 1 plexiform neurofibromas
Small molecule, neurological, MEK inhibitor, neurofibromatosis type 1, rare disease, pediatric - Read more

NICE recommends ALK's ITULAZAX tree pollen tablet for adult allergic rhinitis treatment in UK health system
Protein therapy, autoimmune, allergy immunotherapy, allergic rhinitis, pollen allergy, sublingual tablet - Read more

THE GOOD
Business Development & Partnerships

CorestemChemon partners with ATG Lifetech to develop transcriptomics and organoid platforms for improved preclinical drug development services
Research collaboration, drug discovery, preclinical, organoids, transcriptomics, regulatory - Read more

Klotho Neurosciences, AAVnerGene partner to accelerate gene therapy development for neurodegenerative diseases using advanced AAV platforms
Manufacturing agreement, gene therapy, neurological, neurodegenerative disease, longevity, AAV technology - Read more

NeOnc, Quazar sign sub-license agreement advancing $50M partnership for brain cancer treatments in MENA region
Licensing deal, neurological, oncology, regional expansion, equity investment - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Scancell's iSCIB1+ cancer vaccine shows 69% response rate in Ph2 melanoma trial, advances to pivotal study
Vaccine, cancer, cancer vaccine, melanoma, combination therapy, checkpoint inhibitor - Read more

Livzon's IL-17A/F inhibitor LZM012 achieves Ph3 primary endpoint for plaque psoriasis, outperforming secukinumab
Small molecule, autoimmune, IL-17 inhibitor, plaque psoriasis, dual-target - Read more [Press release in Chinese]

Sanofi, AstraZeneca's Beyfortus shows 87% efficacy against respiratory syncytial virus in Ph4 real-world study
Antibody, infectious disease, monoclonal antibody, respiratory syncytial virus (RSV), preventive therapy, pediatric population - Read more

American Gene Technologies' AGT103-T shows reduced HIV reservoirs in Ph1 trial for functional cure
Cell therapy, infectious disease, gene therapy, HIV, functional cure, reservoir reduction - Read more

Abivax's obefazimod demonstrates positive Ph3 results in ulcerative colitis, meeting key endpoints despite 25mg dose variability
Small molecule, autoimmune, ulcerative colitis, oral therapy, clinical trials - Read more

THE GOOD
Fundraises

Avalyn raises $100M Series D to advance inhaled versions of lung disease medications
Pulmonary fibrosis, inhaled delivery, lung disease, clinical-stage, drug reformulation - Read more

Gesynta Pharma raises $4.3M Series B, developing mPGES-1 inhibitor for endometriosis treatment
Endometriosis, chronic pain, small molecule, clinical-stage, platform technology - Read more

SAB BIO raises $175M in private placement, funding Phase 2b trial for type 1 diabetes therapy
Autoimmune, type 1 diabetes, immunotherapy platform, clinical-stage, antibody - Read more

MEI Pharma raises $100M private placement, adopts Litecoin as treasury reserve asset
Cryptocurrency, treasury management, digital asset, financial strategy - Read more

Pharvaris raises $150M in public offering, advancing late-stage bradykinin-mediated disease treatments
Hereditary angioedema, rare disease, small molecule, oral therapy, late-stage - Read more

THE GOOD
Lawsuits

AbbVie wins $56M royalty award from Revance for Botox patent infringement, securing 15% ongoing royalties
Neurotoxin therapy, aesthetic medicine, patent infringement, legal settlement, financial impact - Read more

THE GOOD
Mergers & Acquisitons

Sanofi acquires Vicebio for $1.6B, adding RSV-hMPV combination vaccine to respiratory portfolio
Protein-based vaccine, infectious disease, strategic acquisition, major transaction - Read more

Concentra acquires struggling iTeos Therapeutics for $10.047 per share plus contingent value rights
Monoclonal antibody, oncology, strategic, major transaction - Read more

THE GOOD
Product Launches

PhoreMost unveils GlueSEEKER platform for rational, systematic molecular glue drug discovery, expanding the druggable proteome
Drug discovery, molecular glue, small molecule, protein degradation, drug development - Read more

THE BAD
Approvals & Labels

FDA rejects Replimmune's RP1 viral immunotherapy for advanced melanoma despite Ph3 IGNYTE trial results
Immunotherapy, cancer, oncolytic virus, melanoma, viral vector, checkpoint inhibitor combination - Read more

FDA panel rejects Otsuka and Lundbeck's Rexulti-sertraline combo for PTSD treatment, citing insufficient efficacy evidence
Small molecule, neurological, regulatory, efficacy concerns - Read more

THE BAD
Regulatory

UK watchdog condemns Theramex for systemic compliance failures in women's health drug marketing
Hormone replacement therapy, women's health, regulatory, compliance, operational - Read more

FDA panel questions antidepressant safety during pregnancy, calls for stricter labeling
Small molecule, mental health, regulatory, safety concern, pregnancy risk - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here